Biophytis S.A.

ALBPS

FR001400OLP5

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 08:18:56 16/07/2024 pm IST			5-day change	1st Jan Change
0.5689 ^EUR	-0.19%		-0.54%	-72.11%

12/07	BIOPHYTIS : Invest Securities confirms its recommendation	CF
11/07	Biophytis Secures US FDA Approval for Mid-stage Study of Obesity Drug	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Biophytis S.A.

BIOPHYTIS : Invest Securities confirms its recommendation	12/07	CF
Biophytis Secures US FDA Approval for Mid-stage Study of Obesity Drug	11/07	MT
Biophytis: approval for a clinical trial in the USA	11/07	CF
Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity	11/07	CI
Biophytis SA Presents Roll-Out and Results of Its Phase 2-3 Cova Study Results in Severe Forms of Covid-19 At the World Congress on Infectious Diseases	01/07	CI
Biophytis: cash position strengthened, share price soars	20/06	CF
Biophytis Extends Bond Financing Deal with Investment Fund Atlas	20/06	MT
Biophytis S.A. Grants Blanver Exclusive Rights to Bio101 in Latin America in Deal Valued At Up to ?108 Million	20/06	CI
Biophytis S.A. Announces the Successful Industrial Transfer of Bio101 (20-Hydroxyecdysone) Production by Its Service Provider Seqens	14/06	CI
Biophytis Files Investigational New Drug Application with US FDA for Mid-stage Obesity Drug Trial	10/06	MT
Biophytis: application filed in obesity in the USA	10/06	CF
Biophytis SA Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity	10/06	CI
Biophytis unveils design for obesity study	14/05	CF
Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity	14/05	CI

Biophytis S.A. is a biotechnology company in the clinical stage specialized in the development of drug candidates to slow degenerative processes and improve functional capacity in patients with age-related diseases, including respiratory failure in patients suffering from COVID-19. The company is located in Paris, France and Cambridge, Massachusetts.

Sector

Biotechnology & Medical Research

Calendar

29/10/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOPHYTIS S.A.	-72.11%	32.66L
VERTEX PHARMACEUTICALS INCORPORATED	+21.84%	13TCr
REGENERON PHARMACEUTICALS, INC.	+24.87%	12TCr
ARGENX SE	+26.93%	2.77TCr
BIONTECH SE	-18.58%	2.03TCr
GENMAB A/S	-15.22%	1.68TCr
BEIGENE, LTD.	-17.68%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+13.50%	1.48TCr
WUXI APPTEC CO., LTD.	-47.10%	1.46TCr
SAREPTA THERAPEUTICS, INC.	+57.74%	1.44TCr